Cisplatin in renal transplant recipients : not an absolute contraindication

Research Projects

Organizational Units

Journal Issue

Abstract

The chemotherapeutic agent cisplatin is usually contraindicated in renal transplant recipients due to its well-known side effect of nephrotoxicity, but is an important (and sometimes irreplaceable) drug in the management of cancer. We report a case of cisplatin usage concurrently with radiation (CRT) in unresectable head and neck cancer, along with a review of the literature.

Table of Contents

DOI

PubMed ID

Degree

Thesis Department

Rights

OpenAccess.

License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License.